JNP Medi-Medirama Launch Jointly Developed Anticancer New Drug Development Solution

Clinical trial data platform company JNP Medi (JNP Medi) and anticancer drug development strategy consulting firm Medirama announced on the 21st that they have launched a full-cycle service that can accelerate success throughout the entire process of anticancer drug development through a strategic partnership.

JNP Medi (top) and Medirama logos
[Photo by each company]

This service is the first collaborative result following the ‘Anticancer Drug Development Business Agreement’ signed by the two companies. It was developed by combining Medirama’s clinical development consulting ABCD (Advanced Business model for Clinical Development) platform and JNP Medi’s clinical trial data platform ‘Maven Clinical Cloud.’ Through this, the plan is to provide clients with a one-stop service that supports business throughout the complex process of anticancer drug development.

Medirama’s ABCD platform is a platform that provides consulting covering the entire process from early clinical development planning to joint development and commercialization. In particular, based on a high level of expertise in anticancer drug clinical development, it leads business consulting encompassing clinical development strategy establishment, regulatory response, and clinical operations. JNP Medi’s Maven Clinical Cloud offers technology that efficiently manages clinical trial data and enables decentralized clinical trials, maximizing efficiency.

Through this, the two companies plan to present optimized solutions in the anticancer drug development process. By introducing such a one-stop service, client companies are expected to be able to develop protocols based on global-level clinical development strategies, conduct professional clinical trial operations, and manage clinical data efficiently. It is also expected to drastically reduce the cost and time required for anticancer drug development and significantly increase the success rate.

Jung Kwon-ho, CEO of JNP Medi, said, "We expect a synergy effect that can maximize the success of drug development by combining the expertise and technological capabilities of both companies," adding, "We will bring about a groundbreaking change especially in the field of anticancer drug development, where the success rate is low." Moon Han-lim, CEO of Medirama, also said, "We will respond quickly to client demands and support success," adding, "We will become a navigator that presents the shortcut to drug development based on the expertise of both companies and a deep understanding of the clinical development process for companies aiming for global anticancer drugs."